Tags

Type your tag names separated by a space and hit enter

Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
Hepatobiliary Pancreat Dis Int. 2009 Jun; 8(3):329-31.HP

Abstract

BACKGROUND

Extramedullary pancreatic plasmacytoma treated with bortezomib is rarely reported.

METHODS

We admitted a 53-year-old woman with an asymptomatic mass above the left clavicle for over three months, then an asymptomatic swelling of the pancreas was found. A biopsy on the mass and a fine needle aspiration of the pancreas were performed. The diagnosis of extramedullary plasmacytoma (EMP) was made. The patient was initially treated with combination chemotherapy consisting of vincristine, doxorubicin and dexamethasone (VAD regimen). She progressed to painless jaundice during the chemotherapy. Then she was treated with bortezomib and hyper-dose dexamethasone. As a result, she had a near complete remission.

RESULTS

The data demonstrated that the diagnosis was EMP of the pancreas. The patient responded very well to bortezomib, while failing to respond to the traditional chemotherapy regimen of VAD.

CONCLUSION

EMP of the pancreas is rare. This case gives evidence for an excellent response of EMP of the pancreas to bortezomib.

Authors+Show Affiliations

Department of Hematology, Institute of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

19502179

Citation

Wei, Ju-Ying, et al. "Bortezomib in Treatment of Extramedullary Plasmacytoma of the Pancreas." Hepatobiliary & Pancreatic Diseases International : HBPD INT, vol. 8, no. 3, 2009, pp. 329-31.
Wei JY, Tong HY, Zhu WF, et al. Bortezomib in treatment of extramedullary plasmacytoma of the pancreas. Hepatobiliary Pancreat Dis Int. 2009;8(3):329-31.
Wei, J. Y., Tong, H. Y., Zhu, W. F., Liu, H., Zhang, F. J., Yu, W. J., & Jin, J. (2009). Bortezomib in treatment of extramedullary plasmacytoma of the pancreas. Hepatobiliary & Pancreatic Diseases International : HBPD INT, 8(3), 329-31.
Wei JY, et al. Bortezomib in Treatment of Extramedullary Plasmacytoma of the Pancreas. Hepatobiliary Pancreat Dis Int. 2009;8(3):329-31. PubMed PMID: 19502179.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bortezomib in treatment of extramedullary plasmacytoma of the pancreas. AU - Wei,Ju-Ying, AU - Tong,Hong-Yan, AU - Zhu,Wei-Fang, AU - Liu,Hui, AU - Zhang,Feng-Juan, AU - Yu,Wen-Juan, AU - Jin,Jie, PY - 2009/6/9/entrez PY - 2009/6/9/pubmed PY - 2009/10/6/medline SP - 329 EP - 31 JF - Hepatobiliary & pancreatic diseases international : HBPD INT JO - Hepatobiliary Pancreat Dis Int VL - 8 IS - 3 N2 - BACKGROUND: Extramedullary pancreatic plasmacytoma treated with bortezomib is rarely reported. METHODS: We admitted a 53-year-old woman with an asymptomatic mass above the left clavicle for over three months, then an asymptomatic swelling of the pancreas was found. A biopsy on the mass and a fine needle aspiration of the pancreas were performed. The diagnosis of extramedullary plasmacytoma (EMP) was made. The patient was initially treated with combination chemotherapy consisting of vincristine, doxorubicin and dexamethasone (VAD regimen). She progressed to painless jaundice during the chemotherapy. Then she was treated with bortezomib and hyper-dose dexamethasone. As a result, she had a near complete remission. RESULTS: The data demonstrated that the diagnosis was EMP of the pancreas. The patient responded very well to bortezomib, while failing to respond to the traditional chemotherapy regimen of VAD. CONCLUSION: EMP of the pancreas is rare. This case gives evidence for an excellent response of EMP of the pancreas to bortezomib. SN - 1499-3872 UR - https://www.unboundmedicine.com/medline/citation/19502179/Bortezomib_in_treatment_of_extramedullary_plasmacytoma_of_the_pancreas_ DB - PRIME DP - Unbound Medicine ER -